CIK 0001815776
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 844867570
- Phone
- +1 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- 4 Exercise or conversion Chief Commercial Officer acquired 3,333 shares (option exercise)
- 4 Exercise or conversion President, CEO and Secretary acquired 45,000 shares (option exercise)
- 4 Open-market buy Chief Financial Officer bought 3,188 shares at $15.68 ($49,988)
- 4 Open-market buy Director bought 31,332 shares at $15.99 ($501,093)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 998,009 shares at $15.03 ($15,000,075)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 589,267 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Medical Officer acquired 99,599 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 3 of 7 · 129 filings